EISAI CO

Clinical trials for Alzheimer's drugs, like Eli Lilly's Kisunla and Eisai's Leqembi, often lack diversity, excluding racial minorities, ApoE4 homozygotes, and patients with comorbidities. This underrepresentation hampers the validation of eligibility criteria in diverse populations, necessitating new cutoffs. Challenges include socioeconomic barriers and inadequate outreach, impacting trial enrollment and patient care.

Large drug-maker stocks surged, driven by FDA approvals and pipeline innovations. Eli Lilly, Roche, Novartis, and Pfizer are top picks for long-term gains. Eli Lilly's tirzepatide drugs and Novo Nordisk's semaglutide drugs are top sellers. Despite M&A scrutiny, activities remained strong. Large drug-makers offer robust revenue streams and profitability.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.

The EMA's refusal to approve lecanemab, a drug for early Alzheimer's, contrasts with its approval in multiple countries. Critics argue the EMA overestimated risks and underestimated benefits, despite manageable side effects. The EMA's exclusion of researchers with industry ties, seen as a conflict of interest, may hinder objective assessments and slow drug approvals.

Nivolumab plus gemcitabine/cisplatin chemotherapy significantly improved response rates, overall survival, and progression-free survival in patients with lymph node–only metastatic urothelial carcinoma, according to a post hoc analysis of the CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.

Foscenvivint, a drug candidate targeting various cancers and administered intravenously or orally, is under development. Eisai, a pharmaceutical company specializing in neurology and oncology, manufactures and markets pharmaceuticals globally. GlobalData provides analytics on drug development likelihood and approval.

Eisai and Biogen's Leqembi and Eli Lilly's Kisunla are first anti-amyloid antibodies to slow Alzheimer's cognitive decline. 32 therapeutics in Phase III trials target neuroprotection, neurotransmitters, neurogenesis, inflammation, and proteinopathies. Leqembi and Kisunla have limited efficacy and notable side effects, prompting diverse opinions on clinical benefit. Next-gen therapeutics aim for easier administration and multiple pathways to treat Alzheimer's.

ESMO 2024 in Barcelona will feature discussions on cancer therapeutics, including anticipated presentations on bispecific antibodies and anti-TIGIT therapies. Other topics include radioligand therapies and synthetic lethality assets. Experts are optimistic about the potential of these therapeutic classes, despite past challenges.

Leqembi, an Alzheimer's drug from Biogen and Eisai, offers early-stage patients more independent living time but faces hurdles like reimbursement issues, diagnostic tests, and neurologist availability. Missie Meeks, an early recipient, reports improved daily functioning. Despite risks like brain swelling and bleeding, some patients find the process worth it for extended normal life.

Leqembi, an Alzheimer's drug from Biogen and Eisai, promises to extend patients' normal, independent lives, though it's not a cure. Missie Meeks, diagnosed with early Alzheimer's, benefits from Leqembi, which moderately slows cognitive decline. However, the drug's rollout faces challenges like insurance hurdles and limited neurologist availability. Despite risks of brain swelling and bleeding, some patients find the process worth it for extended quality time with loved ones.